Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 268 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: First Line Non-Small Cell Lung Cancer Clear all

Conditions: First Line Non-Small Cell Lung Cancer
Interventions: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 21
States / cities: Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more

Conditions: Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Interventions: IO102-IO103 in combination with pembrolizumab; Drug
Lead sponsor: IO Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Duarte, California • Sacramento, California • San Diego, California + 6 more

Conditions: Malignant Neoplasm
Interventions: MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota

Conditions: Non-Small Cell Lung Cancer
Interventions: MK-3475, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 31
States / cities: Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more

Conditions: Non-small Cell Lung Cancer
Interventions: sunvozertinib, Pemetrexed+carboplatin; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Glendale, California • Vallejo, California • Aurora, Colorado + 10 more

Conditions: Non-small Cell Lung Cancer
Interventions: encorafenib, binimetinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 112
States / cities: Yuma, Arizona • Los Angeles, California • Santa Monica, California + 61 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Interventions: AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 14
States / cities: Anaheim, California • Santa Rosa, California • West Hills, California + 10 more

Conditions: Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma, BRAF-Mutated Melanoma
Interventions: TP-0903; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 89
States / cities: Little Rock, Alaska • Hot Springs, Arkansas • Chula Vista, California + 69 more

Conditions: Non-small Cell Lung Cancer, Postmenopausal Women
Interventions: fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions: Pemetrexed, BIBW 2992, Cisplatin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Montebello, California • Miami, Florida + 4 more

Conditions: Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 43
States / cities: Duarte, California • Encinitas, California • Fresno, California + 25 more

Conditions: Non-small Cell Lung Cancer
Interventions: TLK286, cisplatin; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, PEMETREXED, CARBOPLATIN, PACLITAXEL, InVision; Drug · Diagnostic Test
Lead sponsor: Julia K. Rotow, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • Brighton, Massachusetts • South Weymouth, Massachusetts

Conditions: Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg; Drug · Biological · Dietary Supplement
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more

Conditions: Non-Small Cell Lung Cancer
Interventions: bevacizumab, erlotinib HCl, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 4
States / cities: Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 604
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 426 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: nivolumab + ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Pembrolizumab SC, Pembrolizumab IV, Paclitaxel, Nab-Paclitaxel, Carboplatin, Cisplatin, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Fullerton, California • Los Alamitos, California + 14 more

Search by objective public record fields.

Avelumab in First-line NSCLC (JAVELIN Lung 100)

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Plasma-Adapted First-Line Pembro In NSCLC

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)